With the development of chest CT, in particular high-resolution computed tomography (HRCT), for screening high-risk populations for lung cancer, the sensitivity of sub-solid pulmonary nodule (SSN) detection is gradually increased. On HRCT scans, sub-solid pulmonary nodules manifest as pure ground glass nodule (GGN) or part-solid nodule. There is evidence that SSNs have a higher probability of becoming malignant than solid nodules. Henschke et al. (
1) reported that 63% of the part-solid nodules are malignant, while kim et al. (
2) reported that up to 81% of persistent SSNs are malignant. Most of persistent SSNs are pathologically diagnosed as lung adenocarcinoma (
2).
According to the 7th edition of the tumor-node-metastasis (TNM) staging system for all solid tumors, the size of the tumor is one of the important factors that influence the prognosis of patients with lung adenocarcinoma, and the largest diameter of the tumor is a quantitative index reflecting the size of the tumor. According to the TNM staging system, ground glass opacity (GGO) component should be included when measuring the largest diameter of tumor of lung adenocarcinoma manifesting as SSN, but SSN-type and solid nodule-type lung adenocarcinomas have different prognoses even through the same T stage (i.e., the same largest diameter), and with the increase in GGO ratio, SSN-type lung adenocarcinoma has a better prognosis (
3). On HRCT scans, GGO component pathologically represents clara cells or atypical proliferating alveolar epithelial type II cells with lepidic growth, but without interstitial infiltrates (
4). Inclusion of GGO component when measuring the largest diameter of tumor will overestimate the T factor (
5). Murakawa et al. (
5) performed a study of patients with T1-2N0M0 and found that solid component size measured by CT influences tumor recurrence and survival rate. However, GGO component shows little influence on these two indices. Therefore, it is likely to be more significant to measure the largest diameter of solid component during the T stage of a tumor. According to the criteria for lung adenocarcinoma classification issued by international association for the study of lung cancer, American thoracic society, and European respiratory society (IASLC/ATS/ERS) in 2011, solid component should be included when measuring the size of lesions (
6). The criteria for lung adenocarcinoma classification are also an important index used to select the clinical treatment method of SSNs detected by HRCT (
7). However, no matter for tumor T staging or for pathological classification, the largest diameter of tumor is determined by pathological measurement, which can be achieved postoperatively, and therefore, the largest diameter of tumor is not convincible evidence for preparation of individualized treatment program and prognosis judgment. HRCT is an important method for diagnosing lung adenocarcinoma manifesting as SSN. Few studies have been reported regarding the correlation between HRCT and pathological measurements of the size of SSNs, and the discrepancy between these two measurements greatly influences tumor classification and prognosis judgment. The size of tumors of the abdomen and pelvis, such as cervical cancer (
8-
10) is consistent between CT and pathological measurements, but as for non-small cell lung cancer, CT tumor size is slightly larger than pathological tumor size (
11,
12), which occurs possibly because of alveolar collapse during pathological measurement, different fixations of pathologic specimen, and the difficulty in discriminating the boundary between fibrous connective tissue and tumor tissue on HRCT scans. Lee et al. (
13) reported that the largest diameter of GGNs measured by HRCT was significantly greater than that measured pathologically (P < 0.0001), but they did not demonstrate the influence of GGO ratio on the discrepancy between these two measurements.